Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer

  • Michail Ignatiadis
  • Christos Sotiriou
  • Klaus Pantel

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 195)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Introduction

    1. Front Matter
      Pages 1-1
  3. Minimal Residual Disease and Breast Cancer Metastasis

    1. Front Matter
      Pages 11-11
    2. Elizabeth Comen, Larry Norton
      Pages 13-23
    3. Paloma Bragado, Maria Soledad Sosa, Patricia Keely, John Condeelis, Julio A. Aguirre-Ghiso
      Pages 25-39
  4. Technologies for Circulating Tumor Cell and Disseminated Tumor Cell Detection and Characterization

    1. Front Matter
      Pages 41-41
    2. Astrid E. L. M. Hoeppener, Joost F. Swennenhuis, Leon W. M. M. Terstappen
      Pages 43-58
    3. Ali Asgar. S. Bhagat, Chwee Teck Lim
      Pages 59-67
    4. Anthony Williams, Marija Balic, Ram Datar, Richard Cote
      Pages 87-95
    5. Maryam Lustberg, Kris R. Jatana, Maciej Zborowski, Jeffrey J. Chalmers
      Pages 97-110
    6. Evi S. Lianidou, Athina Markou
      Pages 111-123
    7. Anieta M. Sieuwerts, Stefanie S. Jeffrey
      Pages 125-140
  5. Other Blood-Based Biomarkers

    1. Front Matter
      Pages 141-141
    2. Susanna Cooke, Peter Campbell
      Pages 143-149
    3. Maria Angelica Cortez, James William Welsh, George Adrian Calin
      Pages 151-161
    4. Patrizia Mancuso, Angelica Calleri, Francesco Bertolini
      Pages 163-170
  6. Disseminated Tumor Cells and Circulating Tumor Cells in Breast Cancer Clinical Research and Practice

    1. Front Matter
      Pages 171-171

About this book

Introduction

Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.

 

In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:

 

-  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis?

-  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits?

-  How are DTCs and CTCs relevant to clinical research and practice?

- What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids?

-  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?

 

This book will be of interest and assistance to all who are engaged in the modern management of breast cancer.

Keywords

Breast cancer Circulating nucleic acids Circulating tumor cells Micrometastasis Minimal residual disease

Editors and affiliations

  • Michail Ignatiadis
    • 1
  • Christos Sotiriou
    • 2
  • Klaus Pantel
    • 3
  1. 1., Breast Cancer Translational Res. Lab.Institut Jules BordetBrusselsBelgium
  2. 2., Breast Cancer Translational Res. Lab.Institut Jules BordetBrusselsBelgium
  3. 3.Zentrum für Experimentelle Medizin, Inst. TumorbiologieUniversitätsklinikum Hamburg-EppendorfHamburgGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-28160-0
  • Copyright Information Springer-Verlag Berlin Heidelberg 2012
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine
  • Print ISBN 978-3-642-28159-4
  • Online ISBN 978-3-642-28160-0
  • Series Print ISSN 0080-0015
  • About this book